Quick Takeaways: Why It Matters? The EUAs immediately expand the therapeutic toolkit for a serious, fast-moving parasitic threat, positioning NexGard and NexGard COMBO as go‑to options if New World screwworm spreads beyond current foci in northern Mexico.&nb...
Quick Takeaways: Why It Matters? Full approval elevates KBroVet from a conditional option to the reference standard for potassium bromide in canine idiopathic epilepsy, giving vets greater confidence in its long‑term use. Its once‑daily, chewable, liver...
Quick Takeaways: Why It Matters? MUMS status gives Masivet a clearer US regulatory and commercial path, adding potential 7‑year market exclusivity and grant support on top of its established European use, which should enhance the asset’s value as AB Science courts par...
Quick Takeaways: Why It Matters? The EUA gives producers and vets a vetted, over‑the‑counter preventive option at key intervention points (birth, castration, wounds), strengthening biosecurity plans if New World screwworm encroaches toward US herds. Fo...
Quick Takeaways: Why It Matters? Full approval and label expansion make Vetmedin the standard of care for early-stage MMVD, locking in pimobendan as the only FDA‑approved option for delaying CHF in Stage B2 dogs and driving guideline‑aligned, earli...
Quick Takeaways: Why It Matters? With both TAS and RXE accepted, Loyal moves significantly closer to commercializing the first true longevity drug in veterinary medicine, turning canine lifespan extension into a near-term, rather than speculative, market. If LOY-002 reache...
Dechra Secures FDA Approval for Zygolide (Pergolide) in Equine Pituitary Pars Intermedia Dysfunction
Quick Takeaways: Why It Matters? Zygolide gives vets and owners a lower-cost, FDA-approved alternative for managing PPID, which should improve treatment uptake in senior horses. The focus on flexible dosing and palatability makes long-term therapy more practical in th...
Rank Companies Animal Health Revenue (2023 $M) Animal Health Revenue (2024 $M) Percent change (%) 1 Zoetis 8,544 9,256 8.33 2 MSD Animal Health 5,625 5,877 4.48 3 BI Animal Health 5,213.60...
20. ImmuCell Revenue: $17.47M Founded Year: 1987 Market Cap: Total Employees: ~100 Headquarters: Portland, United States Stock Exchange: NASDAQ 19. Hester Biosciences Revenue: $33.24M Founded Year: 1987 Market Cap: Total Employees: ~600 Headquarters: Gujrat, India Stock Exchange: NSE 18. V...
20. ImmuCell Revenue: $18.6M Founded Year: 1982 Market Cap: $35.11M Total Employees: ~70 Headquarters: Maine, United States Stock Exchange: NASDAQ 19. Hester Pharmaceuticals & Biotech Revenue: $32M Founded Year: 1987 Market Cap: $150.13 Tota...
